BACKGROUND: @entity6542 ( @entity6542 ) represents the only specific treatment that can be offered to @entity56 @entity1 apart from allergen avoidance. @entity6542 has been widely used in @entity2023 . Clinical efficacy has been demonstrated in several controlled clinical trials and depends on the specific allergen the individual @entity1 is sensitive to, the quality and total amount of allergen applied, and the @entity6542 schedule. In classic @entity6542 , gradually increasing dosages of the allergen extract are injected subcutaneously. Several dosage schedules for subcutaneous @entity6542 can be applied. In Cluster- @entity6542 , 2 - 3 injections per day of treatment are given once a week during induction treatment. @entity1 : In this study, we investigated 64 @entity1 (33 female, 31 male) from 18 to 54 years (26.9 +/- 5.1 years) in terms of side-effects of Cluster- @entity6542 during induction treatment. RESULTS: The total amount of enlarged local reactions (> grade 1) was n = 77 or 15.2 % of all injections. Of these, 68 (88 %) were classified as immediate reactions, 8 (11 %) were late phase reactions and 1 (1 %) was immediate as well as late phase reaction. Of all enlarged local reactions, 48 (62 %) were grade 1 reactions, 13 (17 %) were grade 2 reactions, 13 (17 %) were grade 3 reactions and 1 (1 %) was a grade 4 reaction. The total amount of systemic reactions was n = 22 or 4.3 % of all injections. Of these, 19 (86 %) were classified as immediate reactions, 3 (14 %) were delayed reactions. Of all systemic reactions, 18 (82 %) were grade 1 reactions and 4 (18 %) grade 2 reactions. Grade 3 or grade 4 reactions did not occur. There were no differences in gender or age regarding the occurrence of side effects (all p > 0.05). CONCLUSIONS: Frequency and severity of adverse side effects in Cluster- @entity6542 correspond to those in other dosage schedules. On behalf of security aspects, Cluster- @entity6542 could become an interesting alternative dosage schedule for dose increase during @entity6542 . Furthermore, in Cluster- @entity6542 with allergoids, induction treatment can be carried out in two treatment days of approximately 2.5 hours each.

[Cluster-immunotherapy in XXXX : safety aspects of induction therapy with depot allergoids (Purethal)].

@entity6542 :: ('MESH:C562465', 'Disease') :: ['Specific immunotherapy', 'SIT'] @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS'] @entity56 :: ('MESH:D004342', 'Disease') :: ['allergic'] @entity2023 :: ('MESH:D006255', 'Disease') :: ['pollen allergic rhinitis']
@entity2023 :: (MESH:D006255,Disease) :: ['seasonal allergic rhinitis']
